A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure
Titel:
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure
Auteur:
Chien, Kelly S. Rodriguez-Sevilla, Juan Jose Alvarado, Yesid Montalban-Bravo, Guillermo Hammond, Danielle E. Swaminathan, Mahesh Bazinet, Alexandre Kimberley, Jacqueline Bodden, Kristy Schneider, Heather Dong, Xiao Qin Pierce, Sherry A. Huang, Xuelin Jabbour, Elias J. Kantarjian, Hagop M. Garcia-Manero, Guillermo